PMID- 19087674
OWN - NLM
STAT- MEDLINE
DCOM- 20090409
LR  - 20181201
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 88
IP  - 32
DP  - 2008 Aug 19
TI  - [Sequential administration of gefitinib and docetaxel as second-line therapy for 
      advanced non-small cell lung cancer: analysis of 82 cases].
PG  - 2258-62
AB  - OBJECTIVE: To evaluate the efficacy of sequential administration of gefitinib and 
      docetaxel in the second-line therapy for advanced non-small cell lung cancer 
      (NSCLC). METHODS: Eighty-two patients with advanced NSCLC who had received both 
      gefitinib and docetaxel treatment were divided into 2 groups: Group A (n = 17) 
      that were treated with gefitinib first and then crossed over to docetaxel 
      treatment when progressive disease (PD) occurred as second-line treatment, and 
      Group B (n = 65) that were treated with docetaxel first, and then crossed over to 
      gefitinib treatment when PD occurred. RESULTS: The response rate of gefitinib in 
      phase I (duration before crossover) was 27.7%, not significantly different from 
      that in phase II (duration after crossover) (29.4%, P > 0.05). The response rate 
      of docetaxel in phase I was 13.8%, not significantly different from that in phase 
      II (5.9%, P > 0.05). Gefitinib showed an efficacy superior to docetaxel after 
      adjusting the sequence of these two agents (28.0% vs 12.2%, chi2 = 5.46, P = 
      0.02). The time to progression (TTP) of gefitinib was 6.0 months, significantly 
      longer than that of docetaxol (4.0 months, P = 0.00). Though no statistically 
      significant survival difference was seen between these two groups, stratified 
      analysis showed that the median survival time of the patients with the Eastern 
      Cooperative Oncology Group (ECOG) = 2 in Group A was 13.0 months, significantly 
      longer than that in Group B (6.0 months, P = 0.01). The adverse events (AEs), 
      including skin rash and diarrhea were all generally tolerable. The incidence of 
      AEs was similar in these two groups. CONCLUSION: Although no impact was found in 
      the efficacy and survival between these two different sequential administration 
      of gefitinib and docetaxel for patients with advanced NSCLC, but the patients 
      with poor performance status may get longer survival if they receive treatment of 
      gefitinib first crossed-over to docetaxel.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical 
      Sciences & Peking Union Medical College, Beijing 100021, China.
FAU - Zhang, Xiang-ru
AU  - Zhang XR
FAU - Wang, Hui-jie
AU  - Wang HJ
FAU - Wang, Bin
AU  - Wang B
FAU - Chu, Da-tong
AU  - Chu DT
FAU - Sun, Yan
AU  - Sun Y
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Quinazolines)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Docetaxel
MH  - Drug Administration Schedule
MH  - Female
MH  - Gefitinib
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Quinazolines/administration & dosage
MH  - Retrospective Studies
MH  - Taxoids/administration & dosage
MH  - Treatment Outcome
EDAT- 2008/12/18 09:00
MHDA- 2009/04/10 09:00
CRDT- 2008/12/18 09:00
PHST- 2008/12/18 09:00 [entrez]
PHST- 2008/12/18 09:00 [pubmed]
PHST- 2009/04/10 09:00 [medline]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2008 Aug 19;88(32):2258-62.